Abstract
Type 1 diabetes is an organ-specific autoimmune disease characterized by T-cell mediated destruction of pancreatic β-cells. A variety of environmental and genetic factors are involved in the development of the disease. The human leukocyte antigen (HLA) class II genes (termed IDDM1) are the major genes associated with susceptibility to type 1 diabetes. The highest risk for type 1 diabetes in Caucasian population is associated with individuals expressing both DRB1*0301-DQB1*0201 and DRB1*0401-DQB1*0302. However, HLA-DRB1*0405-DQB1*0401, HLADRB1* 0901-DQB1*0303 and HLA-DRB1*0802-DQB1*0302 are three major susceptible haplotypes in Japanese patients with type 1 diabetes. In contrast, the most protective HLA DR-DQ haplotype, DRB1*1501-DQB1*0602, is universal. Other genetic factors reported in type 1 diabetes include the polymorphisms in insulin gene (IDDM2), CTLA4 gene (IDDM12), PTPN22 gene, IL-18 gene, TNF-α gene, Neuro D/BETA 2 gene, Vitamin D receptor gene, and SDF-1 gene. Within the last decade, a number of immunological and environmental manipulations in animal models of type 1 diabetes, NOD mouse and BB rat, have been reported. In humans, two major trials have been conducted to try to prevent type 1 diabetes with administration of insulin and nicotinamide (DPT-1 and ENDIT). To date, no treatment has been shown to prevent human type 1 diabetes. However, if a safe and effective therapy is identified, one should consider the use of agent for high risk individuals to prevent diabetes, as well as for the patients with type 1 diabetes in adults who are often diagnosed as having type 2 diabetes to preserve residual β-cell function based on the findings of both immunogenetic and pharmacogenetic testing to predict responders from non-responders.
Keywords: type diabetes, autoantibodies, genetics, heterogeneity, immunology, autoantigen
Current Pharmacogenomics
Title: Molecular Genetics and Epidemiology of Japanese Type 1 Diabetes
Volume: 3 Issue: 3
Author(s): Eiji Kawasaki and Katsumi Eguchi
Affiliation:
Keywords: type diabetes, autoantibodies, genetics, heterogeneity, immunology, autoantigen
Abstract: Type 1 diabetes is an organ-specific autoimmune disease characterized by T-cell mediated destruction of pancreatic β-cells. A variety of environmental and genetic factors are involved in the development of the disease. The human leukocyte antigen (HLA) class II genes (termed IDDM1) are the major genes associated with susceptibility to type 1 diabetes. The highest risk for type 1 diabetes in Caucasian population is associated with individuals expressing both DRB1*0301-DQB1*0201 and DRB1*0401-DQB1*0302. However, HLA-DRB1*0405-DQB1*0401, HLADRB1* 0901-DQB1*0303 and HLA-DRB1*0802-DQB1*0302 are three major susceptible haplotypes in Japanese patients with type 1 diabetes. In contrast, the most protective HLA DR-DQ haplotype, DRB1*1501-DQB1*0602, is universal. Other genetic factors reported in type 1 diabetes include the polymorphisms in insulin gene (IDDM2), CTLA4 gene (IDDM12), PTPN22 gene, IL-18 gene, TNF-α gene, Neuro D/BETA 2 gene, Vitamin D receptor gene, and SDF-1 gene. Within the last decade, a number of immunological and environmental manipulations in animal models of type 1 diabetes, NOD mouse and BB rat, have been reported. In humans, two major trials have been conducted to try to prevent type 1 diabetes with administration of insulin and nicotinamide (DPT-1 and ENDIT). To date, no treatment has been shown to prevent human type 1 diabetes. However, if a safe and effective therapy is identified, one should consider the use of agent for high risk individuals to prevent diabetes, as well as for the patients with type 1 diabetes in adults who are often diagnosed as having type 2 diabetes to preserve residual β-cell function based on the findings of both immunogenetic and pharmacogenetic testing to predict responders from non-responders.
Export Options
About this article
Cite this article as:
Kawasaki Eiji and Eguchi Katsumi, Molecular Genetics and Epidemiology of Japanese Type 1 Diabetes, Current Pharmacogenomics 2005; 3 (3) . https://dx.doi.org/10.2174/1570160054864030
DOI https://dx.doi.org/10.2174/1570160054864030 |
Print ISSN 1570-1603 |
Publisher Name Bentham Science Publisher |
Online ISSN 1570-1603 |
Related Articles
-
NF-κB, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Porphyrin Metabolisms in Human Skin Commensal Propionibacterium acnes Bacteria: Potential Application to Monitor Human Radiation Risk
Current Medicinal Chemistry Pernicious Anemia: Fundamental and Practical Aspects in Diagnosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting BLyS in Systemic Lupus Erythematosus
Recent Patents on Inflammation & Allergy Drug Discovery siRNA Delivery Using Nanocarriers – An Efficient Tool for Gene Silencing
Current Gene Therapy Expression and Function of Cytokines and Chemokines in Neuropsychiatric Related Systemic Lupus Erythematosus
Current Rheumatology Reviews Evidence that Pregnancy Specific Glycoproteins Regulate T-Cell Function and Inflammatory Autoimmune Disease During Pregnancy
Current Drug Targets - Inflammation & Allergy The Prevalence of the Classical and Non-Classical Cardiovascular Risk Factors in Multiple Sclerosis Patients
CNS & Neurological Disorders - Drug Targets Modulation of TNF Receptor Family Members to Inhibit Autoimmune Disease
Current Drug Targets - Inflammation & Allergy CD26 / Dipeptidyl Peptidase IV: A Regulator of Immune Function and a Potential Molecular Target for Therapy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders A Key Role for Altered Dendritic Cell Functioning in the Impaired Immunity Seen in Aged Individuals
Current Immunology Reviews (Discontinued) Migraine in Systemic Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of CTLA-4 Gene Polymorphisms in Autoimmune Disease Pathogenesis: A 2012 Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Biological Activities, Mechanisms of Action and Biomedical Prospect of the Antitumor Ether Phospholipid ET-18-OCH3 (Edelfosine), A Proapoptotic Agent in Tumor Cells
Current Drug Metabolism Regulation of Protective and Pathogenic Th17 Responses
Current Immunology Reviews (Discontinued) Emerging Treatment Strategies and Potential Therapeutic Targets in Primary Sjogrens Syndrome
Inflammation & Allergy - Drug Targets (Discontinued) A Potential Therapeutic Target RNA-binding Protein, Arid5a for the Treatment of Inflammatory Disease Associated with Aberrant Cytokine Expression
Current Pharmaceutical Design Immuno - Functionalized Silver Nanoparticles for Diagnostics, Therapeutics and Protection of Rabies Viral Infection
Current Nanomedicine NF-κB Inhibitors for the Treatment of Inflammatory Diseases and Cancer
Current Medicinal Chemistry Mesenchymal Stromal Cells in Rheumatoid Arthritis: Biological Properties and Clinical Applications
Current Stem Cell Research & Therapy